The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 03, 2018

Filed:

Dec. 02, 2014
Applicant:

Iomet Pharma Ltd., Edinburgh, Midlothian, GB;

Inventors:

Phillip Martin Cowley, Edinburgh, GB;

Alan Wise, Edinburgh, GB;

Margaret Huggett, Dundee, GB;

Assignee:

IOmet Pharma Ltd., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/551 (2006.01); A61K 31/404 (2006.01); C07D 401/04 (2006.01); C07D 403/12 (2006.01); C07D 401/12 (2006.01); C07D 403/04 (2006.01); C07D 405/12 (2006.01); C07D 413/12 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 209/34 (2006.01); C07D 209/40 (2006.01); C07D 513/04 (2006.01); A61K 31/435 (2006.01); A61K 31/4439 (2006.01); A61K 31/444 (2006.01); A61K 31/454 (2006.01); A61K 31/4545 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/5377 (2006.01); A61K 31/55 (2006.01); A61K 45/06 (2006.01); C07D 209/20 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 403/06 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 471/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/551 (2013.01); A61K 31/404 (2013.01); A61K 31/435 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 45/06 (2013.01); C07D 209/20 (2013.01); C07D 209/34 (2013.01); C07D 209/40 (2013.01); C07D 401/04 (2013.01); C07D 401/06 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 513/04 (2013.01);
Abstract

Provided is a tryptophan-2,3-dioxygenase (TDO) and/or indoleamine-2,3-dioxygenase (IDO) inhibitor compound for use in medicine, which compound comprises the following formula: wherein X, X, X, and Xmay be the same or different and each is independently selected from C and N; X, X, X, X, X, X, and Xmay be the same or different and each is independently selected from C, N and O; each bond having a dotted line may independently be a double bond or a single bond, provided that valencies at each atom are maintained; the dotted lines joining Xwith the carbon atoms either side of Xare single bonds, and are only present when Xis absent, Xis absent and Xis C, and when these bonds are present the ring carbons on each side of Xare not directly bonded to each other; each Rmay be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of Rgroups present is such that the valency of Xis maintained; each R, R, R, R, Rand Rmay be present or absent and may be the same or different and each is independently selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valency of the ring carbon atoms is maintained; Rmay be present or absent and is selected from H and a substituted or unsubstituted organic group, provided that the number of Rgroups present is such that the valency of Xis maintained; each Rmay be present or absent and may be the same or different and is independently selected from H and a substituted or unsubstituted organic group, provided that the number of Rgroups present is such that the valency of Xis maintained; each R, R, R, and Rmay be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X, X, X, and Xare maintained; each R, Rand Rmay be present or absent and may be the same or different and is selected from H and a substituted or unsubstituted organic group, provided that the number of such R groups present is such that the valencies of X, X, and Xare maintained; and Ris selected from H and a substituted or unsubstituted organic group, preferably H and a substituted or unsubstituted C-Calkyl group; and wherein any R group may form a ring with any other R group on an adjacent and/or proximal atom.


Find Patent Forward Citations

Loading…